An encounter of the developing immune system with an antigen results in the induction of immunological areactivity to this antigen. In the case of transplantation antigens, the application of allogeneic hematopoietic cells induces a state of neonatal transplantation tolerance. This tolerance depends on the establishment of cellular chimerism, when allogeneic cells survive in the neonatally treated recipient. Since mesenchymal stem/stromal cells (MSCs) have been shown to have low immunogenicity and often survive in allogeneic recipients, we attempted to use these cells for induction of transplantation tolerance. Newborn (less than 24 h old) C57BL/6 mice were injected intraperitoneally with 5 × 106 adipose tissue-derived MSCs isolated from allogeneic donors and the fate and survival of these cells were monitored. The impact of MSC application on the proportion of cell populations of the immune system and immunological reactivity was assessed. In addition, the survival of skin allografts in neonatally treated recipients was tested. We found that in vitro expanded MSCs did not survive in neonatal recipients, and the living MSCs were not detected few days after their application. Furthermore, there were no significant changes in the proportion of individual immune cell populations including CD4+ cell lineages, but we detected an apparent shift to the production of Th1 cytokines IL-2 and IFN-γ in neonatally treated mice. However, skin allografts in the MSC-treated recipients were promptly rejected. These results therefore show that in vitro expanded MSCs do not survive in neonatal recipients, but induce a cytokine imbalance without induction of transplantation tolerance.

Department of Cell Biology Faculty of Science Charles University 12843 Prague 2 Czech Republic

Department of Nanotoxicology and Molecular Epidemiology Institute of Experimental Medicine of the Czech Academy of Sciences 14220 Prague 4 Czech Republic

Zobrazit více v PubMed

Billingham, R. E., Brent, L., & Medawar, P. B. (1953). Actively acquired tolerance of foreign cells. Nature (Lond.), 172, 603–605 DOI

Hasek, M. (1953). Vegetative hybridization of animals by joing their blood circulations during embryonic life. Csech Biology, 2, 265–277

Holan, V., Chutna, J., & Hasek, M. (1978). Specific suppression of antigen-reactive cells in neonatal transplantation tolerance. Nature (Lond.), 274, 895–897 DOI

Burnet, F. M. (1959). The clonal selection theory of acquired immunity. Cambridge University Press DOI

Nossal, G. J. (1991). Molecullar and cellular aspects of immunologic tolerance. European Journal of Biochemistry, 202, 729–737

Schwartz, R. H. (2003). T cell anergy. Annual Review of Immunology, 21, 305–334

Dorsch, S., & Roser, B. (1975). T cells mediate transplantation tolerance. Nature (Lond.), 258, 233–235 DOI

Gao, Q., Rouse, T. M., Kazmerzak, K., & Field, E. H. (1999). CD4 + CD25 + cells regulate CD8 cell anergy in neonatal tolerant mice. Transplantation, 68, 1891–1897 DOI

Lubaroff, D. M., Silvers, W. K. (1973). Importance of chimerism in maintaining tolerance of skin allografts in mice. Journal of Immunology, 111, 65–71

Durkin, E. T., Jones, K. A., Rajesh, D., & Shaaban, A. F. (2008). Early chimerism threshold predicts sustained engraftment and NK-cell tolerance in prenatal allogeneic chimeras. Blood, 112, 5245–5253 DOI

Zuber, J., & Sykes, M. (2017). Mechanisms of mixed chimerism-based transplant tolerance. Trends in Immunology, 38, 829–843

Oura, T., Cosimi, A. B., & Kawai, T. (2017). Chimerism-based tolerance in organ transplantation: preclinical and clinical studies. Clinical and Experimental Immunology, 189, 190–196 DOI

Sellers, M. T., Deierhoi, M. H., Curtis, J. J., Gaston, R. S., Julian, B. A., Lanier, D. C. Jr., & Diethelm, A. G. (2001). Tolerance in renal transplantation after allogeneic bone marrow transplantation-6-year follow-up. Transplantation, 71, 1681–1683

Nunez-Villaveiran, T., Feasel, P., Keenan, S., Aliotta, R., Bosler, D., Stearns, D., Bergfeld W. & Gurunluoglu, R. (2019). Donor skin allograft survival after bone marrow transplantation: Case report and systematic review of the literature. Journal of Plastic, Reconstructive and Aesthetic Surgery, 72, 23–34

Muñoz-Elias, G., Marcus, A. J., Coyne, T. M., Woodbury, D. & Black, I. B. (2004). Adult bone marrow stromal cells in the embryonic brain: engraftment, migration, differentiation, and long-term survival. Journal of Neuroscience, 24, 4585–4595

Dai, W., Hale, S. L., Martin, B. J., Kuang, J.-Q., Dow, J. S., Wold, L. E. & Kloner, R. A. (2005). Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short- and long-term effects. Circulation, 112, 214–223

Tzameret, A., Sher, I., Belkin, M., Treves, A. J., Meir, A., Nagler, A. … Solomon, A. S. (2015). Epiretinal transplantation of human bone marrow mesenchymal stem cells rescues retinal and vision function in a rat model of retinal degeneration. Stem Cell Research, 15, 387–394

Caliari-Oliveira, C., Yaochite, J. N., Ramalho, L. N., Palma, P. V., Carlos, D., Cunha Fde, Q. … Voltarelli, J. C. (2016). Xenogeneic mesenchymal stromal cells improve wound healing and modulate the immune response in an extensive burn model. Cell Transplantation, 25, 201–215

Liu, X. B., Chen, H., Chen, H. Q., Zhu, M. F., Hu, X. Y., Wang, Y. P. … Wang, J. A. (2012). Angiopoietin-1 preconditioning enhances survival and functional recovery of mesenchymal stem cell transplantation. Journal of Zhejiang University - Science B, 13, 616–623

Eggenhofer, E., Benseler, V., Kroemer, A., Popp, F. C., Geissler, E. K., Schlitt, H. J., & Hoogduijn, M. J. (2012). Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Frontiers in Immunology, 3, 297 DOI

Abdi, R., Fiorina, P., Adra, C. N., Atkinson, M., Sayegh, M. H. (2008). Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes, 57, 1759–1767

Holan, V., Trosan, P., Cejka, C., Javorkova, E., Zajicova, A., Hermankova, B. ... Cejkova, J. (2015). A comparative study of the therapeutic potential of mesenchymal stem cells and limbal epithelial stem cells for ocular surface reconstruction. Stem Cells and Translation Medicine, 4, 1052–1063 DOI

Weiss, A. R. R., & Dahlke, M. H. (2019). Immunomodulation by mesenchymal stem cells (MSCs): Mechanisms of action of living, apoptotic, and dead MSCs. Frontiers in Immunology, 10, 1191. https://doi.org/10.3389/fimmu.2019.01191

de Witte, S. F. H., Luk, F., Sierra Parraga, J. M., Gargesha, M., Merino, A., Korevaar, S. S. … Hoogduijn, M. J. (2018). Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells. Stem Cells, 36, 602–615

Preda, M. B., Neculachi, C. A., Fenyo, I. M., Vacaru, A. M., Publik, M. A., Simionescu, M., & Burlacu, A. (2021). Short lifespan of syngeneic transplanted MSC is a consequence of in vivo apoptosis and immune cell recruitment in mice. Cell Death and Disease, 12, 566 DOI

Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L., & Luo, L. (2007). A global double-fluorescent Cre reporter mouse. Genesis, 45, 593–605

Holan, V., Echalar, B., Palacka, K., Kossl, J., Bohacova, P., Krulova, M. … Zajicova, A. (2021). The altered migration and distribution of systemically administered mesenchymal stem cells in morphine-treated recipients. Stem Cell Reviews and Reports, 14, 801–801 DOI

Hajkova, M., Javorkova, E., Zajicova, A., Trosan, P., Holan, V., & Krulova, M. (2017). A local application of mesenchymal stem cells and cyclosporine A attenuates immune response by a switch in macrophage phenotype. Journal of Tissue Engineering and Regenerative. Medicine, 11, 1456–1465 DOI

Lencova, A., Pokorna, K., Zajicova, A., Krulova, M., Filipec, M., & Holan, V. (2011). Graft survival and cytokine production in the experimental mouse model of limbal transplantation. Transplant Immunology, 24, 189–194 DOI

Billingham, R. E., Brent, L., Medawar, P. B., & Sparrow, E. M. (1954). Quantitative studies on tissue transplantation immunity. I. The survival times of skin homografts exchanged between members of different inbred strains of mice. Proceedings of the Royal Society of London B: Biological Sciences, 143, 43–58

Hajkova, M., Jaburek, F., Porubska, B., Bohacova, P., Holan, V. & Krulova, M. (2009). Cyclosporine A promotes the therapeutic effect of mesenchymal stem cells on transplantation reaction. Clinical Science (Lond.), 133, 2143–2157

Hasek, M., & Holan, V. (1981). Relative immunogenecity and tolerogenicity of individual regions or segments of the MHC. Scandinavian Journal of Immunology, 14, 669–672 DOI

Bandeira, A., Coutinho, A., Carnaud, C., Jacquemart, F., & Forni, L. (1989). Transplantation tolerance correlates with high levels of T- and B-lymphocyte activity. Proceedings of the National Academy of Sciences of the United States of America, 86, 272–276

Holan, V., Sedlackova, K. & Ruzickova, M. (1996). Production of high levels of Th1 and Th2 cytokines in mice with acquired transplantation tolerance. Cellular Immunology, 174, 7–12

Chen, N., Gao, Q, Field, E. H. (1996). Prevention of Th1 response is critical for tolerance. Transplantation, 61, 1076–1083

Tracy, S. A., Chalphin, A. V., Lazow, S. P., Kycia, I., Finkelstein, A., Chan, C. … Fauza, D. O. (2020). Postnatal fate of donor mesenchymal stem cells after transamniotic stem cell therapy in a healthy model. Journal of Pediatric Surgery, 55, 1113–1116

Liao, X., Li, F., Wang, X., Yanoso, J., Niyibizi, C. (2008). Distribution of murine adipose-derived mesenchymal stem cells in vivo following transplantation in developing mice. Stem Cells and Development, 17, 303–314

Wagner, W., Ho, A. D., & Zenke, M. (2010). Different facets of aging in human mesenchymal stem cells. Tissue Engineering Part B Reviews, 16, 445–453 DOI

Rombouts, W. J., & Ploemacher, R. E. (2003). Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia, 17, 160–170 DOI

Chua, B. A., & Signer, R. A. J. (2020). Hematopoietic stem cell regulation by the proteostasis network. Current Opinions in Hematology, 27, 254–263 DOI

Muhammad, G., Xu, J., Bulte, J. W. M., Jablonska, A., Walczak, P. & Janowski, M. (2017). Transplanted adipose-derived stem cells can be short-lived yet accelerate healing of acid-burn skin wounds: a multimodal imaging study. Scientific Reports, 7(1):4644

Chen, Y., Tristan, C. A., Chen, L., Jovanovic, V. M., Malley, C., Chu, P.-H., Ryu, S., Deng, T., Ormanoglu, P., Tao, D., Fang, Y., Slamecka, J., Hong, H., LeClair, C. A., Michael, S., Austin, C. P., Simeonov, A., Singeç, I. (2021). A versatile polypharmacology platform promotes cytoprotection and viability of human pluripotent and differentiated cells. Nature Methods, 18, 528–541

Hu, J., Yu, X., Wang, Z., Wang, F., Wang, L., Gao, H., Chen, Y., Zhao, W., Jia, Z., Yan, S., Wang, Y. (2013). Long term effects of the implantation of Wharton’s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocrinology Journal, 60, 347–357

Abumaree, M., Jumah, M. A., Pace, R. A., Kalionis, B. (2012). Immunosuppressive properties of mesenchymal stem cells. Stem Cell Reviews and Reports, 8, 375–392

Holan, V., Hermankova, B., Krulova, M., & Zajicova, A. (2019). Cytokine interplay among diseased retina, inflammatory cells and mesenchymal stem cells – a clue to stem cell-based therapy. World Journal of Stem Cells, 11, 957–967 DOI

Luk, F., de Witte, S. F., Korevaar, S. S., Roemeling-van Rhijn, M., Franquesa, M., Strini, T. … Hoogduijn, M. J. (2016). Inactivated mesenchymal stem cells maintain immunomodulatory capacity. Stem Cells and Development, 25, 1342–1354

Perspectives and Limitations of Mesenchymal Stem Cell-Based Therapy for Corneal Injuries and Retinal Diseases